ASCO-GU – Bicycle tries to put distance between itself and Seagen

Since Bicycle’s BT8009 is one of only four nectin-4-targeting industry projects apart from Seagen’s Padcev, its maker is positioning it as a key pipeline asset. Yesterday brought more data suggesting that BT8009 might have a future in Padcev’s approved use of urothelial bladder cancer.